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Introduction: Multiple organ dysfunction is the main cause of death in severe acute pancreatitis.
Primary mitochondrial dysfunction plays a central role in the development and progression of organ failure
in critical illness. The present study investigated mitochondrial function in seven tissues during early
experimental acute pancreatitis.
Methods: Twenty-eight male Wistar rats (463  2 g; mean  SEM) were studied. Group 1 (n = 8), saline
control; Group 2 (n = 6), caerulein-induced mild acute pancreatitis; Group 3 (n = 7) sham surgical controls;
and Group 4 (n = 7), taurocholate-induced severe acute pancreatitis. Animals were euthanased at 6 h from
the induction of acute pancreatitis and mitochondrial function was assessed in the heart, lung, liver,
kidney, pancreas, duodenum and jejunum by mitochondrial respirometry.
Results: Significant early mitochondrial dysfunction was present in the pancreas, lung and jejunum in
both models of acute pancreatitis, however, the Heart, liver, kidney and duodenal mitochondria were
unaffected.
Conclusions: The present study provides the first description of early organ-selective mitochondrial
dysfunction in the lung and jejunum during acute pancreatitis. Research is now needed to identify the
underlying pathophysiology behind the organ selective mitochondrial dysfunction, and the potential
benefits of early mitochondrial-specific therapies in acute pancreatitis.
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Introduction
Multiple organ dysfunction syndrome (MODS) is the main cause
of death in both the early and late phases of severe acute pancre-
atitis.1,2 In the initial 2 weeks of severe acute pancreatitis,MODS is
caused by exaggerated cytokine-mediated systemic inflammatory
response syndrome (SIRS) which is thought to primarily affect the
lungs,3–5 whereas in the latter phase MODS is secondary to sepsis
thought to result from intestinal barrier failure.1,6 Mortality from
severe acute pancreatitis correlates with the number of organs that
fail,7 and the presence of MODS has also been shown to identify
patients most at risk of death.8 The response of early organ failure
to initial resuscitation and intensive care support is also predictive
of outcome.1,3 For example, resolution of organ failure with resus-
citation within 48 h confers good prognosis, whereas persistent
organ failure does not.1,2 Development of novel therapies for acute
pancreatitis associated MODS has been frustrated by a lack of
understanding of the underlying pathophysiological processes
during early severe acute pancreatitis.9
Recent research has linked mitochondrial dysfunction (MD)
with MODS.10–13 Primary MD during SIRS, recently termed
‘cytopathic hypoxia’, is now thought to play a central role in the
development and progression of MODS.14–16 This primary mito-
chondrial failure is postulated to lead to metabolic failure and*These authors contributed equally to this paper.
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eventual organ dysfunction.13,16 In addition to cytopathic hypoxia,
disruption of the mitochondrial electron transport system (ETS,
complexes I–IV, which are responsible for oxidative phosphoryla-
tion) in a disease state can result in the excess release of reactive
oxygen species (ROS), usually in the form of superoxide (O2·-)
from complexes I and III.17 Excess ETS-derived ROS cause further
oxidative damage to the mitochondria, which can not only impair
respirational flux but also lead to increased mitochondrial perme-
ability with the concomitant release of cytochrome c, a well-
defined apoptotic mediator.17 Thus,MDmay kill cells by excessive
ROS production, energy starvation and/or apoptosis.
Here, we hypothesise that MD occurs in distant organs early
during the development of acute pancreatitis and before the
development of MODS. Confirmation of MD in distant organ
systems during the early phase of acute pancreatitis would
support the proposal that mitochondrial-specific therapies may
help prevent the subsequent development of MODS in severe
acute pancreatitis as the disease progresses.
The aim of the present study was to characterise mitochondrial
function in seven tissue homogenates using high-resolution
respirometry during early acute pancreatitis in two different
rodent models.
Methods
Ethical approval and study design
The present study was approved by the University of Auckland
Animal Ethics Committee. Twenty-eight male Wistar rats (6–8
months old, 463  2 g; mean  SEM), fed a standard Harlan
Teklad 2018 rodent diet (Madison,WI, USA) were randomised to
four groups: Group 1 (n = 8), saline control; Group 2 (n = 6),
caerulein-induced acute pancreatitis (CIP); Group 3 (n = 7) sham
surgical controls (laparotomy only without induction of pancre-
atitis); and Group 4 (n = 7), taurocholate-induced acute pancre-
atitis (TIP, a laparotomy followed by intraductal infusion of
taurocholate into the pancreas).18,19 All chemicals used in these
experiments were supplied by Sigma Aldrich Pty Ltd (New South
Wales, Australia), unless otherwise stated.
Caerulein-induced pancreatitis model
Mild CIP was induced by four subcutaneous (s.c.) injections of
20 mg/kg caerulein, a cholecystokinin analogue, in a total of 0.8 ml
of 0.9% NaCl at hourly intervals.20,21 Analgesia was by bup-
renorphine (0.05 mg/kg, s.c.; Temgesic ®, Reckitt and Coleman,
Hull, England). Saline controls were treated with 0.9% NaCl
(normal saline) s.c. only.
Taurocholate-induced pancreatitis model
Balanced general anaesthesia was induced andmaintained by isof-
lurane (2–5%; 2 l/min O2 via nasal cone) and buprenorphine
(0.05 mg/kg, s.c.). Body temperature was maintained between
36–38°C by use of a warming plate. All animals received 5 ml of
SC normal saline administered at the start of the experimental
protocols, after which the common pancreatic duct was cannu-
lated with a 24-G angiocath passed transduodenally through the
Ampulla of Vater through a 1.5-cm abdominal midline incision.
The rostral part of the animal was raised 60° to the horizontal for
5 min to allow the bile duct system to drain (~0.1 ml). During the
last 2 min of this procedure, the common hepatic duct was
occluded at the hilum (Biemer atraumatic vascular clip; Aesculap,
Center Valley, PA, USA).
Sodium taurocholate (4% w/v in 0.9% NaCl; 0.1 ml/100 g BW)
was infused at 0.1 ml/min by a controlled infusion pump (Genie
Precision Pump; Kent Scientific, Torrington, CT, USA). The
Biemer clip and angiocath were removed upon completion of the
infusion, and the common pancreatic duct was ligated to prevent
reflux of taurocholate into the duodenum. The abdomen was then
closed and the rat recovered on a warming plate.
In the post-operative phase, all animals were individually
housed, had access to food and tap water ad libitum for 6 h and
were monitored as per a standard post-operative recovery proto-
col; thereafter, they were rapidly anaesthetised under isoflurane.
Blood was collected for biochemical assays by a euthanising
cardiac puncture and stored at -80°C until analysis, whereas the
various tissues analysed were then rapidly excised, chilled in ice-
cold phosphate-buffered solution (PBS) buffer, and used fresh for
the respective mitochondrial studies.
Mitochondrial respiration assay
We employed high-resolution respirometry with a previously
published substrate-inhibitor protocol that permitted rapid
analysis of ETS function and integrity in tissue homogenates as
well as permeabilised cardiac fibres.22,23 We elected to use tissue
homogenates because these provided a means for rapid simulta-
neous processing of the several tissues for measurement of tissue-
specific mitochondrial respirational flux rate. Homogenates were
also considered superior to mitochondrial isolation in this experi-
mental setting as they sum the entire mitochondrial population
present in tissue samples. This approach avoids the processing
delays of enriched organelle preparations as well as the risk of any
potential confounding bias that can result if swollen, more fragile
and/or damaged mitochondrial subpopulations are lost through
the processing steps required for pure mitochondrial isolation.23–25
The tissues studied were: the pancreas (tail and head sepa-
rately), duodenum, mid-jejunum, lung (left lower lobe), heart
(left ventricular endomyocardium), left kidney and liver (left
lobe). All tissues with the exception of the left ventricular
endomyocardium, were cut into small pieces (~2 mm2), quickly
blotted dry, weighed and placed into ice-cold respiration assay
media [0.5 mM EGTA, 3 mM MgCl2, 60 mM K-lactobionate,
20 mM taurine, 10 mM KH2PO4, 110 mM sucrose and 1 mg/ml
bovine serum albumin (BSA) in 20 mM HEPES, pH 7.1 at 30°C]
containing one Complete™ protease inhibitor tablet (Roche, Basel,
Switzerland) per 30 ml and 20 mg/ml fatty acid free BSA. These
tissues were homogenised immediately before assay. The perme-
abilised left ventricular endomyocardial fibers were prepared
according to a published methodology.22 Approximately 25 mg
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was placed into a droplet of ice-cold high-energy relaxing solution
[10 mMEGTA-Ca2EGTA buffer (free Ca2+ concentration 0.1 mM),
9.5 mM MgCl2, 3 mM KH2PO4, 20 mM taurine, 5 mM ATP,
15 mM creatine phosphate, 49 mM K+ MES, 29 mM imidazole-
HCl, pH 7.1] and dissected into fibre bundles of ~0.5 ¥ 1 mm. The
dissected fibre bundles were transferred into 1 ml of fresh high-
energy relaxing solution plus 50 mg saponin and gently stirred for
30 min at 4°C for permeabilisation. They were then washed three
times in ice-cold respiration medium to remove the saponin and
adenine nucleotides. Fibre bundles were then weighed after
removing adherent liquid by blotting on lint-free lens tissue.
Mitochondrial respiration wasmeasured in parallel 2-ml cham-
bers using an OROBOROS® Oxygraph 2 K (Anton Paar, Graz,
Austria). The respiratory measurements were performed at 30°C
and the oxygen concentration at air saturation of the medium was
215 nmol O2 per ml at 95 kPa barometric pressure.26 For pancre-
atic and intestinal tissues, an additional 10 mg/ml of fatty acid-
free BSA was added to the respiration medium.
A specially designed substrate/inhibitor titration approach
allowed the step-by-step analysis of several mitochondrial com-
plexes within the one experiment.27 This substrate-inhibitor titra-
tion protocol has previously been used in our laboratory28,29 and
by others.30,31 This permitted tests of the: ‘state 2’ or leak state
respiration (LEAK); oxidative phosphorylation flux with
Complex I and Complex I and II substrates (OXP-I, and OXP-
I,II); uncoupled electron transport chain flux (ETS); ETS flux on
Complex II substrates alone (ETS-II); and cytochrome c oxidase
flux (CCO). Therefore, this protocol provided rapid insight into
the phosphorylation capacity of mitochondria and components
of the ETS, as well as testing inner and outer membrane integri-
ties, all in a single rapid experiment.
The protocol started with the addition of: (inmMunless stated)
10 glutamate and 5malate (LEAK-I); followed by 1.25 ADP (OXP-
1); 5 succinate (OXP-1,2), two to three additions of 0.5 mM car-
bonyl cyanide p-(trifluoro-methoxy) phenyl-hydrazone (FCCP,
ETS-I,II), 1 mM; 1 mM rotenone (ETS-II); antimycin A, 5 mM
N’-tetramethyl-p-phenylendiamine (TMPD) with 0.5 ascorbate
(CCO), and finally 5 mM cytochrome c (CCOc). The addition of
the metabolic inhibitors rotenone and antimycin provided an
indication of non-specific oxidation. Figure 1 illustrates a typical
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Figure 1 Representative trace generated by the OROBOROS® Oxygraph 2 K. Solid line represents mitochondrial respiration (left y-axis) and
the dotted line represents the oxygen concentration (right y-axis). LEAK: state 2 respiration with glutamate and malate. OXP-I: oxidative
phosphorylation with Complex I substrates (state 3 respiration) with the addition of adenosine diphosphate (ADP). OXP-I,II: state 3
respiration with succinate a Complex II substrate. ETS-I,II: uncoupled respiration with addition of carbonylcyanide-4-(trifluoromethoxy)-
phenylhydrazone (FCCP). ETS-I,II: addition of rotenone. CCO: addition of tetramethyl-p-phenylenediamine (TMPD)/ascorbate. CCOc
addition of cytochrome C. Cyto C: cytochrome C. Ant A: antimycin A. Concomitant oxygen concentration (nmol/ml) is shown on the right
y-axis
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tracing of mitochondrial respiratory flux obtained during a single
representative experiment.
Total protein concentrations were determined for pancreas,
intestine, liver, kidney and lung samples using Biuret reagent
with BSA as standard and the respiration medium as blank. Flux
rates were determined using DatLab 4 Analysis Software
(OROBOROS®, Austria) and reported as weight-specific oxygen
flux (pmol O2/mg protein/second) for all tissues except the heart,
which was reported as pmol O2/mg wet weight/second.
Incubation of lung tissue with caerulein
In a separate experiment, we determined whether there might be
any direct toxic effect of caerulein on rodent lung mitochondria.
Lung tissue (n = 4) was incubated with 200 mg/kg caerulein at
37°C for 30 min in oxygenated assay medium. Control lung tissue
(n = 4) was incubated similarly in the oxygenated assay medium.
Mitochondrial respiration was measured as described above.
Histology and assays
Pancreatic tissue was fixed (10% neutral buffered formalin), and
blinded histological severity scoring was performed by a consult-
ant histopathologist on 5-mm thick longitudinal paraffin sections
using haematoxylin and eosin stain. The score assessed leukocyte
infiltration, pancreatic oedema, haemorrhage, fat necrosis and
acinar necrosis using a published scoring system.32
All biochemical assays with the exception of amylase were per-
formed using a Roche/Hitachi MODULAR® analytical system
(Roche Diagnostics GmbH, Mannheim, Germany) in accordance
with the manufacturer’s instructions. Amylase was measured on a
COBAS MIRA analyser (Roche) using a commercial reagent set
(Pointe Scientific, Michigan, USA) according to the manufactur-
er’s instructions.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism ™
version 4.00 for Macintosh (GraphPad Software, San Diego, Cali-
fornia, USA). The Mann–Whitney U-test with a Bonferroni cor-
rection was used for the three relevant planned comparisons. A
P-value < 0.05 was considered significant.
Results
All animals survived the study protocols. Both CIP and TIP
models produced acute pancreatitis with the expected elevation in
serum amylase (Table 1). There was no clinical or biochemical
evidence of established MODS being present at this early time
point in either model. The TIP model produced a more severe
acute pancreatitis than the CIP model, as shown by the higher
histology scores in the TIP group (Table 1). The serum creatinine
and electrolyte measurements were unchanged in the CIP group
compared with matched controls (saline-control group). The
mild nature of the CIP model was also confirmed by the lack of
any other biochemical derangement (Table 1). By contrast, the
TIP model had a modest systemic derangement in various bio-
chemical parameters (Table 1).
Effect of acute pancreatitis on the
pancreatic mitochondria
Pancreatic MD was apparent in both acute pancreatitis models
(Table 2), but its pattern differed between the two. Whereas CIP
lead to a significant depression of glutamate oxidation (complex I
dysfunction with decreased GM2 and GM3 along with increased
(OXP-I/LEAK-I) in the pancreatic tail, it caused only an increase
in the OXP-I,II/OXP-I ratio (indicating Complex I dysfunction
relative to complex II) in the pancreatic head (Table 2). TIP sig-
nificantly depressed flux through Complexes I and II in the pan-
creatic head (Table 2, Fig. 2). TIP induced no significant changes
in mitochondrial function in the pancreatic tail in spite of the tail
being oedematous.
Effect of anaesthesia and surgery on
mitochondrial function
The combination of a volatile anaesthetic and surgery depressed
respiratory flux through Complex I, Complex II and isolated
Complex IV (CCO) in the lung when compared with the non-
operated saline control group (Table 2, Fig. 2) thus preventing the
investigation of lung MD in the TIP model.
Sham surgery also impacted pancreatic mitochondrial function
in spite of there being no significant difference between the pan-
creas histology scores from the saline control and sham surgical
groups (Table 1). Depressed Complex I flux was seen in both the
pancreatic head and tail while depression of Complex II was
limited to the pancreatic tail. The heart, liver, kidney, duodenal
and jejunal mitochondrial function were not altered in the sham
surgical group (Table S1).
Effect of acute pancreatitis on distant organ
mitochondrial function
MD secondary to pancreatitis in distant organs was restricted to
the lung and jejunum (Table 2, Fig. 2). CIP depressed flux through
Complexes I, II and IV in lung tissues. Respirational flux through
Complex I was also depressed in jejunal homogenates when com-
pared with the saline control group. TIP caused jejunal Complex
I and II dysfunction when compared with sham surgery. However,
there was no difference in the lung mitochondrial function
between the TIP group vs. sham surgery, where the combination
of the anaesthetic and surgery appeared to depress overall lung
mitochondrial function in the sham group, potentially masking
any effect of TIP. Neither model of acute pancreatitis at 6 h had
any significant impact on mitochondrial respiration in the heart,
liver, kidney or duodenum (Table S1).
No direct effect of caerulein on lung
mitochondrial function
The lung appeared to be the most susceptible to MD induced by
pancreatitis or surgery (Table 2). Therefore, in order to exclude a
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direct toxic effect of the caerulein on the lung, an additional
experiment was performed in which lung tissue was incubated
directly with 10 times the concentration of caerulein used in the in
vivo study. The results show no significant alteration in lung mito-
chondrial function as a result of the direct effects of caerulein
(Table 3).
Discussion
The present study has characterised mitochondrial function in
seven tissues 6 h after the induction of acute pancreatitis in two
accepted rodent models of acute pancreatitis. The key findings
were that the inflamed pancreas itself showed significant MD in
both models and that in other organs distant from the pancreas
the MD was highly selective in its distribution. This is the first
study to document early and selective MD in the lungs and
jejunum during early acute pancreatitis and before the develop-
ment of MODS.
The first organ system to demonstrate dysfunction and to fail in
clinical severe acute pancreatitis is the lung.33 In our own experi-
ence, 88% of patients with severe acute pancreatitis had estab-
lished respiratory failure within the first week of hospitalisation.4
It has also been shown that about half of the deaths within the first
week of severe acute pancreatitis can been attributed to respira-
tory failure.34–36 Experimental models of acute pancreatitis have
also demonstrated early lung injury. It has been reported that
within 3 h of caerulein administration in rats it was possible to
demonstrate decreased surfactant synthesis, alveolar capillary
endothelial injury and increased neutrophil infiltration, and that
these effects were not as a result of a direct effect of caerulein on
the lung.36,37
Here, we report for the first time that there is a significant
depression of lung mitochondrial function, with reductions in
Complex I and II respiratory flux occurring within 6 h of the
induction of mild acute pancreatitis by caerulein. Healthy lung
function and viability are known to be directly related to normal
mitochondrial function,38,39 and failure of mitochondrial respira-
tion and oxidative phosphorylation has been considered an
important part of the complex pathophysiology of adult respira-
tory dysfunction syndrome.40 An early impairment of lung
Table 1 Diagnostic, histological, and physiological markers of severity in the different experimental groups
Test Saline control Caerulein-induced mild
pancreatitis
Sham surgery Taurocholate-induced
severe pancreatitis
Histological score1 1.0  0.2a 4.8  0.5a,c 0.7  0.2b 8.9  0.3b,c
Amylase
(U/l)
1489  152a 5990  458a,c 1409  150b 12 848  1 909b,c
Sodium
(mmol/l)
132.8  1.4 137.0  2.1 136.9  1.3 130.0  1.7
Potassium
(mmol/l)
4.7  0.2 4.6  0.2 4.7  0.1 5.2  0.3
Chloride
(mmol/l)
95.9  1.2 99.0  1.3 97.4  1.9 91.0  2.3
Glucose
(mmol/l)
11.0  0.9 11.2  1.3 10.2  1.2 14.3  1.8
Urea 5.8  0.2 6.3  0.1 7.4  1.2b 13.3  1.2b
Creatinine
(mmol/l)
31.8  1.4 35.5  1.3 36.3  2.5b 81.0  14.4b
Calcium
(mmol/l)
2.52  0.04 2.53  0.03 2.56  0.05 2.61  0.05
Albumin
(g/l)
34.6  0.9 35.2  0.8 35.4  0.5 33.6  0.8
Bilirubin
(mmol/l
<2 2 <2 18.9  9.4
GGT
(U/l)
<2 <2 <2 16  2
ALP
(U/l)
84  7 72  14 63  3b 105  11b
AST
(U/l)
83  12 72  21 108  4 5437  2303
ALT
(U/l)
50  4 44  15 56  9b 739  328b
Values are mean  SEM;
1Histology score is for pancreatic tissue. Values for bilirubin <2 and GGT < 2 were below the limit of detection and not quantified further by the
Roche/Hitachi MODULAR® analytical system. Like-letters indicate P < 0.05 for the Mann–Whitney U-tests with Bonferroni's correction.
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Table 2 Effect of surgery, caerulein-induced mild pancreatitis and taurocholate-induced severe pancreatitis on mitochondrial function (lung,
jejunum and pancreas)
Tissue Saline control Caerulein-induced
mild pancreatitis
Sham surgery Taurocholate-induced
severe pancreatitis
Lung
LEAK 10.8  0.9b 8.1  1.2 4.2  0.3b 4.8  0.4
OXP-I 71.5  7.8a,b 42.8  5.1a 27.3  1.7b 26.8  2.5
OXP-I,II 98.7  11.2a,b 61.6  7.4a 38.7  3.0b 38.0  3.7
ETS 107.4  14.9b 67.7  8.3 41.7  4.2b 42.1  3.4
ETS-II 55.8  9.5 41.9  5.1 26.0  2.2 28.8  3.8
CCO 144.4  22.9a,b 73.6  10.5a 56.6  5.0b 59.3  5.6
CCOc 199.7  27.4b 160.2  43.7 86.8  5.4b 86.6  12.1
OXP-I,II/ OXP-I 1.4  0.0 1.4  0.0 1.4  0.0 1.4  0.0
ACR 6.6  0.4 5.6  0.5 6.9  0.8 5.6  0.1
Jejunum
LEAK 22.2  3.7 18.8  2.2 24.5  1.8 13.7  3.7
OXP-I 123.1  21.3 98.2  12.7 117.1  8.8c 44.4  10.1c
OXP-I,II 212.1  37.2 202.8  26.8 200.6  52.9c 73.0  17.4c
ETS 171.4  31.2 183.0  31.6 158.2  20.6c 53.7  12.7c
ETS-II 115.0  21.5 110.5  20.3 95.1  14.4c 37.9  8.7c
CCO 174.2  21.1 194.1  20.0 182.2  16.3 132.4  32.7
CCOc 337.7  41.7 297.5  30.8 353.2  22.8 269.0  58.8
OXP-I,II/ OXP-I 1.7  0.1a 2.1  0.0a 1.7  0.1 1.7  0.1
ACR 5.4  0.48 5.2  0.3 5.0  0.5 4.4  0.6
Pancreas head
LEAK 31.9  6.2b 21.0  2.9 11.4  2.3b,c 3.5  0.5c
OXP-I 137.0  19.7 73.3  8.4 57.6  13.4c 9.3  5.2c
OXP-I,II 240.3  33.0 192.7  24.1 134.0  24.1c 46.1  11.3c
ETS 232.5  32.8 198.5  25.0 139.0  24.0c 47.6  12.7c
ETS-II 177.9  24.7 163.6  20.8 111.4  18.8 45.8  11.8
CCO 411.1  75.9 406.8  86.2 249.5  30.1 230.7  64.7
CCOc 597.8  108.7 541.8  108.3 362.5  61.8 324.9  77.0
OXP-I,II/ OXP-I 1.8  0.1a,b 2.6  0.1a 2.6  0.2b 6.8  1.7
ACR 4.6  0.3 4.1  0.9 5.2  0.8 3.6  2.1
Pancreas tail
LEAK 40.0  2.3a,b 19.0  2.6a 18.2  4.4b 7.5  1.4
OXP-I 146.7  12.3a,b 75.7  12.6a 70.9  19.0b 33.5  6.8
OXP-I,II 247.1  16.5b 180.4  27.6 140.4  30.7b 90.9  12.1
ETS 240.3  15.3a 183.0  27.5 a 139.4  30.7 94.5  13.4
ETS-II 177.3  9.5 146.2  20.9 108.3  23.6 82.5  12.3
CCO 313.5  21.0 265.9  37.9 219.1  42.4 221.2  35.6
CCOc 465.8  28.6 441.4  93.2 332.4  87.4 307.7  41.7
OXP-I,II/ OXP-I 1.7  0.1a,b 2.6  0.4a 2.3  0.3b 3.0  0.4
ACR 3.7  0.3 3.9  0.5 3.9  0.5 4.8  0.8
Units are pmols O2/mg protein/second. LEAK: State 2 respiration with glutamate and malate. GM3: State 3 respiration with addition of adenosine
diphosphate (ADP). Units are pmols O2/mg wet weight/second. OXP-I: State 3 respiration with addition of succinate. ETS: uncoupled respiration with
addition of carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone (FCCP). ETS-II: addition of rotenone. CCO: addition of tetramethyl-p-
phenylenediamine (TMPD)/ascorbate. CCOc addition of cytochrome C. OXP-I,II/OXP-II: provides a measure of complex I contribution to respiration.
ACR: acceptor control ratio. Like letters represent significant differences between those groups (P < 0.05, Bonferroni corrected) whereby aCaerulein
pancreatitis vs. saline control; bSaline control vs. sham surgery; cSham surgery vs. taurocholate pancreatitis.
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mitochondrial function during the development of acute pancre-
atitis would not only cause early deterioration in lung function
through decreased ATP production10 but would also predispose
the lung to further damage evoked by excessive ROS production
and apoptosis,41 contributing to the later development of adult
respiratory dysfunction syndrome.
Volatile anaesthetic and/or sham surgery confounded the inves-
tigation of lung MD in the TIP model. The sham-operated group
showed substantially depressed mitochondrial respiration in the
lung when compared with the saline control (non-operated)
group. Attenuation of the lung mitochondria Complexes I, II and
IV persisted 6 h after recovery from the brief anaesthetic and sham
surgery. This depression of mitochondrial respiration in the lung
may be as a result of a combined effect of the volatile anaesthetic
and the surgical stress associatedwith bowel handling.The effect of
the anaesthetic may be explained by the observation that lung
epithelial cells are among the first to be exposed to highly concen-
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Figure 2 A summary of the effects of caerulein pancreatitis, sham surgery and taurocholate pancreatitis on the various respiratory chain
complexes. For definitions of LEAK-I through to CCOc see legend for Figure 1. ‘-’ represents inhibition of the complex. Letters ‘a’, ‘b’ and
‘c’ represent significant inhibition of the complex whereby a: caerulein pancreatitis vs. saline control; b: sham surgery vs. saline control;
c: taurocholate pancreatitis vs. sham surgery.
Table 3 Pulmonary mitochondrial respiration with and without incu-
bation with caerulein
Tissue Control Incubation with
caerulein
Lung
LEAK 2.6  0.6 2.6  0.7
OXP-I 13.0  2.9 13.0  2.9
OXP-I,II 21.7  4.9 21.4  4.8
ETS 25.6  5.8 25.0  5.7
ETS-II 14.8  3.3 14.8  3.3
CCO 53.2  12.3 42.8  9.3
CCOc 58.4  15.6 58.9  13.0
OXP-I,II/ OXP-I 1.7  0.0 1.6  0.0
ACR 5.1  0.4 5.9  1.1
Units are pmol O2/mg protein/second. For abbreviation descriptions see
footnote Table 2
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trated volatile anaesthetics and may suffer from cytotoxic and
genotoxic effects as a consequence.42 Volatile anaesthetics are
reported to inhibit Complex I,43 open mitochondrial ATP-
inhibited K+ channels which leads to mitochondrial depolarisa-
tion44 and cause depression of themitochondrial respiratory chain
sufficient to cause reversal of Complex V (F1/F0 ATPase),44 which
involves ATP hydrolysis (as opposed to synthesis) in order to
maintain membrane potentials. In addition to the effects of the
anaesthetic, it has previously been reported that amini-laparotomy
and simple handling of the small bowel can cause significant lung
injury with evidence of increased lung permeability and oxidative
stress.45,46 Our finding of lung MD in the sham-operated group is
consistent with these studies. Therefore, the CIP model was better
suited to assessing lung MD in early acute pancreatitis.
Mitochondrial dysfunction in the jejunum within 6 h of the
induction of mild-to-moderate acute pancreatitis in both models
was an important and unexpected finding of the present study.
Previous reports have suggested that the failure of intestinal func-
tion, and more specifically increased permeability and bacterial
translocation, occurs over the course of the first week after the
onset of severe acute pancreatitis.6,9 By contrast, the present study
provides evidence for the first time that intestinal dysfunction,
and more specifically jejunal MD, occurs within hours of the onset
of mild to moderate acute pancreatitis. Our findings challenge
conventional thinking by demonstrating that this early MD in the
jejunum also occurs in less severe acute pancreatitis and occurs
before the development of MODS or hypovolaemic shock. Con-
sistent with our findings is previous work suggesting that intesti-
nal mucosal injury after the induction of endotoxic shock was
independent of hypoperfusion, and might be as a result of
impaired mitochondrial respiration or cytopathic hypoxia.15
Interestingly, no evidence for mitochondrial dysfunction was
found in the duodenum during the present study. It has previously
been reported that the jejunum has areas more susceptible to
ischaemia–reperfusion mucosal injury than the duodenum or
ileum because of differences in vascular anatomy.47 This might be
part of the explanation for our findings of increased MD in the
jejunum but not the duodenum. Other factors, such as differences
in microbes and intra-luminal content48 between the duodenum
and jejunum, might also contribute to differences in mitochon-
drial function and this requires further investigation.
Impairment of intestinal barrier function has been shown to
correlate strongly with subsequent MODS and septic complica-
tions as a result of translocation of bacteria and the priming of
neutrophils.6,9 Intestinal permeability to bacteria was reported to
correlate inversely with enterocyte ATP levels, thereby supporting
the idea that the intestinal barrier function is ATP dependent.49
Early intestinal MD, with its concomitant decrease in ATP pro-
duction and increase in ROS,10,41 may therefore underpin intesti-
nal barrier failure, which then leads to not only the worsening
of MODS by exacerbation of SIRS but also to the delayed septic
complications. Thus our data suggests that jejunal mitochondria
might represent a previously unrecognised and very early event in
acute pancreatitis, long before increased intestinal permeability
and bacterial translocation are thought to occur. As such, jejunal
MD might therefore be understood as a primary step in the sub-
sequent failure of the intestinal barrier function in MODS and
thus offer a newly identified target for early intervention therapy.
There are very few reports of mitochondrial function in tissues
outside of the pancreas in acute pancreatitis. These have been
restricted to the investigation of isolated liver mitochondrial func-
tion in acute pancreatitis where hepatic MD has been reported in
rodents with TIP.50,51 Interestingly, we did not find any change in
the in situ mitochondrial function in liver homogenates during
early pancreatitis in either model at 6 h, and this may reflect
differences in experimental protocols. For example, we gave 5 ml
of SC normal saline for resuscitation at the start of the protocol in
the TIP model, and used tissue homogenates rather than isolated
mitochondria to avoid any potential risk of mitochondrial extrac-
tion stress or artefact.
The development of novel therapies to prevent the progression
of severe acute pancreatitis-associated MODS continues to be
frustrated by a clear understanding of key pathophysiology during
the early stages of severe acute pancreatitis.9 In the present study
we have shown that the early inhibition of mitochondrial respi-
ratory chain complexes is not global but occurs selectively in lung
and jejunum during early acute pancreatitis. Failure of these two
specific organ systems contributes significantly to the morbidity
and mortality associated with severe acute pancreatitis.4,6,9,34 This
early and selective MD seen in the lung and jejunum during the
development of acute pancreatitis offers new insights and avenues
to pursue in the underlying pathophysiological events during the
early phase of acute pancreatitis. Further research is now needed
to document the evolution of MD at multiple time points with
disease progression, and to investigate if mitochondrial-specific
therapies can prevent or aid recovery of lung and jejunal MD.11,13,16
Such an approach has not been considered for the treatment of
acute pancreatitis.
Conclusions
The present study provides the first comprehensive description
of mitochondrial function in multiple organs during early acute
pancreatitis. We have identified a previously unrecognised and
early organ-selective inhibition of mitochondrial function distant
from the primary site of pancreatic inflammatory damage. These
data highlight the need for further research to identify the under-
lying pathophysiology behind the selective MD in these organs,
and the potential benefits of early mitochondrial-specific thera-
pies in acute pancreatitis.
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